Treatment Intervention Advisory Committee Review and Determination

Date: October 31, 2014
To: DHS/DLTC
From: Wisconsin Department of Health Services Autism and other Developmental Disabilities
Treatment Intervention Advisory Committee: Lana Collet-Klingenberg, Ph.D. (chairperson)
RE: Determination of Feldenkrais Therapy as a proven and effective treatment for individuals with autism spectrum disorder and/or other developmental disabilities

☑ This is an initial review
☐ This is a re-review. The initial review was Date of initial review

Section One: Overview and Determination

Please find below a statement of our determination as to whether or not the committee views Feldenkrais Therapy as a proven and effective treatment for children with autism spectrum disorder and/or other developmental disabilities. In subsequent sections you will find documentation of our review process including a description of the proposed treatment, a synopsis of review findings, the treatment review evidence checklist, and a listing of the literature considered. In reviewing treatments presented to us by DHS/DLTC, we implement a review process that carefully and fully considers all available information regarding a proposed treatment. Our determination is limited to a statement regarding how established a practice is in regard to quality research. We do not make funding decisions.

Description of proposed treatment
The Feldenkrais Method is a therapy used to improve movement patterns, reduce physical pain, and improve wellbeing (Claire, 1995, as cited at http://en.wikipedia.org/wiki/Feldenkrais_Method). Per the developer's website (www.feldenkrais.com), it is expressed in two parallel forms: Awareness through Movement and Functional Integration. Awareness through movement consists of verbally directed movement sequences presented primarily to groups. In these lessons, participants engaged in structured movement explorations that involve thinking, sensing, moving, and imagining. The goal of this program is to make one aware of his or her habitual neuromuscular patterns and rigidities and to expand options for new ways of moving while increasing sensitivity and improving efficiency. Functional Integration targets similar movement sequences as the Awareness through Movement program, but utilizes gentle, non-invasive touching.

Synopsis of review
In the case of Feldenkrais Therapy, please refer to the attached reference listing that details the reviewed research. The committee’s conclusions regarding Feldenkrais Therapy include a lack of evaluation with children with autism. That is, the therapy has been evaluated with a variety of disorders, including patients recovering from stroke, fibromyalgia, injuries, and cerebral palsy. The http://www.feldenkrais.com website includes anecdotes of practitioners who work with children with autism and special needs (see http://www.feldenkrais.com/method/article/waking_up_james/; and
http://www.feldenkrais.com/method/article/the_feldenkrais_method_with_atypical_children/). However, no scientific, empirical studies to date have included individuals with autism.

In sum, it is the decision of the committee that Feldenkrais Therapy does not have a study in which participants were clearly identified as having an autism spectrum disorder or developmental disability and no authoritative bodies have recognized the treatment as having emerging evidence, therefore qualifies as a Level 4 - Insufficient Evidence Treatment.
Section Two: Rationale for Focus on Research Specific to Comprehensive Treatment Packages (CTP) or Models

In the professional literature, there are two classifications of interventions for individuals with Autism Spectrum Disorder (National Research Council, 2001; Odom et al., 2003; Rogers & Vismara, 2008):

(a) Focused intervention techniques are individual practices or strategies (such as positive reinforcement) designed to produce a specific behavioral or developmental outcome, and

(b) Comprehensive treatment models are “packages” or programs that consist of a set of practices or multiple techniques designed to achieve a broader learning or developmental impact.

To determine whether a treatment package is proven and effective, the Treatment Intervention Advisory Committee (TIAC) will adopt the following perspective as recommended by Odom et al. (2010):

The individual, focused intervention techniques that make up a comprehensive treatment model may be evidence-based. The research supporting the effectiveness of separate, individual components, however, does not constitute an evaluation of the comprehensive treatment model or “package.” The TIAC will consider and review only research that has evaluated the efficacy of implementing the comprehensive treatment as a package. Such packages are most often identifiable in the literature by a consistently used name or label.


Section Three: DLTC-TIAC Treatment Review Evidence Checklist

Name of Treatment: Feldenkrais Therapy

**Level 1 - Well Established or Strong Evidence (DHS 107 - Proven & Effective Treatment)**

- Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, National Professional Development Center) have approved of or rated the treatment package as having a strong evidence base; authorities are in agreement about the level of evidence.

- There exist ample high quality studies that demonstrate experimental control and favorable outcomes of treatment package.
  - Minimum of two group studies or five single subject studies or a combination of the two.
  - Studies were conducted across at least two independent research groups.
  - Studies were published in peer reviewed journals.

- There is a published procedures manual for the treatment, or treatment implementation is clearly defined (i.e., replicable) within the studies.

- Participants (i.e., N) are clearly identified as individuals with autism spectrum disorders or developmental disabilities.

*Notes:* At this level, include ages of participants and disabilities identified in body of research

**Level 2 – Established or Moderate Evidence (DHS 107 - Proven & Effective Treatment)**

- Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have approved of or rated the treatment package as having at least a minimal evidence base; authorities may not be in agreement about the level of evidence.

- There exist at least two high quality studies that demonstrate experimental control and favorable outcomes of treatment package.
  - Minimum of one group study or two single subject studies or a combination of the two.
  - Studies were conducted by someone other than the creator/provider of the treatment.
  - Studies were published in peer reviewed journals.

- Participants (i.e., N) are clearly identified as individuals with autism spectrum disorders or developmental disabilities.

*Notes:* At this level, include ages of participants and disabilities identified in body of research
Level 3 – Emerging Evidence (DHS 107 – Promising as a Proven & Effective Treatment)

☐ Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have recognized the treatment package as having an emerging evidence base; authorities may not be in agreement about the level of evidence.

☐ There exists at least one high quality study that demonstrates experimental control and favorable outcomes of treatment package.
  ☐ May be one group study or single subject study.
  ☐ Study was conducted by someone other than the creator/provider of the treatment.
  ☐ Study was published in peer reviewed journal.

☐ Participants (i.e., N) are clearly identified as individuals with autism spectrum disorders or developmental disabilities.

Notes: At this level, include ages of participants and disabilities identified in body of research

Level 4 – Insufficient Evidence (Experimental Treatment)

☒ Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have not recognized the treatment package as having an emerging evidence base; authorities are in agreement about the level of evidence.

☐ There is not at least one high quality study that demonstrates experimental control and favorable outcomes of treatment package.
  ☐ Study was conducted by the creator/provider of the treatment.
  ☐ Study was not published in a peer reviewed journal.

☒ Participants (i.e., N) are not clearly identified as individuals with autism spectrum disorders or developmental disabilities.

Notes:
Level 5 – Un tested (Experimental Treatment) &/or Potentially Harmful

☐ Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have not recognized the treatment package as having an emerging evidence base; authorities are in agreement about the level of evidence.

☐ There are no published studies supporting the proposed treatment package.

☐ There exists evidence that the treatment package is potentially harmful.
  ☐ Authoritative bodies have expressed concern regarding safety/outcomes.
  ☐ Professional bodies (i.e., organizations or certifying bodies) have created statements regarding safety/outcomes.

Notes: At this level, please specify if the treatment is reported to be potentially harmful, providing documentation

Date: October 31, 2014

Committee Members Completing Initial Review of Research Base: Jeffrey Tiger, Amy Van Hecke

Committee Decision on Level of Evidence to Suggest the Proposed Treatment is Proven and Effective: Level 4 - Insufficient Evidence (Experimental Treatment)

References Supporting Identification of Evidence Levels:


Section Four: Literature Review


